300194 Stock Overview
Research and develops, produces, and sells chemical drugs in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Fuan Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.77 |
| 52 Week High | CN¥5.68 |
| 52 Week Low | CN¥2.92 |
| Beta | 0.20 |
| 1 Month Change | -4.02% |
| 3 Month Change | 28.57% |
| 1 Year Change | 12.24% |
| 3 Year Change | 5.77% |
| 5 Year Change | -10.84% |
| Change since IPO | -30.43% |
Recent News & Updates
Recent updates
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Shares Fly 36% But Investors Aren't Buying For Growth
Oct 08
There's No Escaping Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Muted Earnings
Aug 23Does Fuan Pharmaceutical (Group) (SZSE:300194) Have A Healthy Balance Sheet?
Jun 07Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit
May 02Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price
Apr 03Shareholder Returns
| 300194 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.4% | -1.9% | -1.2% |
| 1Y | 12.2% | -1.8% | 11.8% |
Return vs Industry: 300194 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 300194 exceeded the CN Market which returned 10.9% over the past year.
Price Volatility
| 300194 volatility | |
|---|---|
| 300194 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300194 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300194's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3,292 | Lu Wang | www.fapharm.com |
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd.
Fuan Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 300194 fundamental statistics | |
|---|---|
| Market cap | CN¥5.67b |
| Earnings (TTM) | CN¥281.63m |
| Revenue (TTM) | CN¥2.66b |
20.1x
P/E Ratio2.1x
P/S RatioIs 300194 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300194 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.66b |
| Cost of Revenue | CN¥1.34b |
| Gross Profit | CN¥1.32b |
| Other Expenses | CN¥1.04b |
| Earnings | CN¥281.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 49.60% |
| Net Profit Margin | 10.59% |
| Debt/Equity Ratio | 16.1% |
How did 300194 perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield22%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fuan Pharmaceutical (Group) Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Everbright Securities Co. Ltd. |
| Guang Wang | Guoyuan Securities Co., Ltd. |
| Yi Yao | Huatai Research |